Image Analysis Group (UK) is a leader in the rapidly growing market for Magnetic Resonance Imaging (MRI) data quantification and analysis, helping partners such as hospitals, CROs and biotech companies design and manage their clinical studies for the most effective use of resources while providing earlier, more convincing evidence of treatment effect with smaller patient cohorts. The company's solution improves the accuracy of diagnostic assessment and research decisions for companies developing treatments for inflammatory musculoskeletal conditions, neuro-inflammation, oncology, cardiac perfusion and rare diseases.
Immusoft (Seattle, USA) develops a first-in-class hybrid cell/gene therapy, which uses a clinically validated, non-viral vector for safe, reliable insertion of functional genes into B-cells. The ISP™ platform enables safe insertion of genes encoding the correct human homolog of a missing or defective protein into a patient’s immune cells using the Sleeping Beauty (SB) Transposon system – a non-viral vector. If successful, the therapy could become a breakthrough in multiple indications with lysosomal storage and protein production disorders.
AGCT (St. Petersburg, Russia) develops a gene therapy against HIV and HIV-linked cancers. The setup is a spin-out from one of the major oncology clinics in Russia and is supported by IP on genome editing from a top EU university. The therapy has the potential to bring cure to previously incurable patients with HIV and lymphomas and could also be used in a number of less severe indications.
An undisclosed investment, this clinical-stage company in the UK is developing a drug against a severe CNS disorder based on research from one of the top universities.